Table IV.
CA IX expression determined by immunohistochemistry and patient clinical characteristics.
| CA IX-positive | CA IX-negative | Proportion of CA IX-stained pixels (%) | Intensity of CA IX-stained pixels | |
|---|---|---|---|---|
| CCRCC (all stages) | 53 | 4 | 6.30 | 119.91 |
| CCRCC stage T1 | 26 | 2 | 6.68 | 124.03 |
| CCRCC stage T3 | 22 | 2 | 5.33 | 115.20 |
| Non-CCRCC | 7 | 6 | 0.24 | 72.58 |
| BT | 1 | 3 | 0.25 | 29.15 |
| p-value | CCRCC vs. non-CCRCC, <0.001 CCRCC vs. BT, <0.001 T1 vs. T3 CCRCC, 0.396 |
CCRCC vs. non-CCRCC, 0.035 CCRCC vs. BT, 0.050 T1 vs. T3 CCRCC, 0.422 |
RCC, renal cell carcinoma; CCRCC, clear cell renal cell carcinoma; PRCC, papillary renal cell carcinoma; CHRCC, chromophobe renal cell carcinoma; BT, benign tumor.